Reproductive medicine & maternal health
Ferring will be the world-leading, most trusted healthcare company in reproductive medicine and women’s health.
Our ambition is to pioneer a new era in fertility where all potential parents are empowered to build families.
Ferring is a world leader in Assisted Reproductive Technology (ART) for fertility treatment. Ferring’s on-going research efforts in this area strive to meet the growing needs of patients as increasing numbers of couples seek help to conceive. Ferring also offers a range of peptide-based medicines to prevent pre-term labour. Ferring has developed MENOPUR® (menotropin) and BRAVELLE® (human follicle stimulating hormone) to stimulate the ovaries, DECAPEPTYL® (gonadotropin releasing hormone agonist) to control the timing of ovary stimulation and CHORAGON® (human chorionic gonadatropin) to induce ovulation.
Research at Ferring into the use of oxytocin antagonists to help manage and prevent pre-term labour, led to the development of TRACTOCILE® (atosiban).
A novel peptide (barusiban) is in advanced clinical trials to aid implantation support in ART.
Ferring is using its recombinant DNA technology platform to develop recombinant gonadotropins to complement its human-derived gonadotropin franchise. Its principal candidate (human recombinant follicle stimulating hormone) is in Phase III studies.
Join the #projectfamily conversation